Health Care [ 6/12 ] | Health Care Equipment & Supplies [ 62/76 ]
NASDAQ | Common Stock
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York.
Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 30, 26 | -0.10 Increased by +47.37% | -0.10 Decreased by -2.56% |
| Nov 17, 25 | -0.10 Increased by +50.00% | -0.11 Increased by +6.28% |
| Aug 13, 25 | -0.10 Increased by +56.52% | -0.11 Increased by +9.09% |
| May 12, 25 | -0.16 Increased by +60.00% | -0.11 Decreased by -41.22% |
| Mar 24, 25 | -0.19 Increased by +24.00% | -0.17 Decreased by -11.76% |
| Nov 13, 24 | -0.20 Increased by +41.18% | -0.22 Increased by +9.09% |
| Aug 12, 24 | -0.23 Increased by 0.00% | -0.22 Decreased by -4.55% |
| May 13, 24 | -0.40 Increased by 0.00% | -0.27 Decreased by -48.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 4.70 B Increased by +392.75 K% | -16.27 M Decreased by -40.94% | Decreased by -0.35% Increased by +99.96% |
| Sep 30, 25 | 1.21 M Increased by +3.33% | -10.40 M Increased by +15.96% | Decreased by -858.55% Increased by +18.66% |
| Jun 30, 25 | 1.16 M Increased by +19.16% | -4.44 M Increased by +59.66% | Decreased by -381.69% Increased by +66.15% |
| Mar 31, 25 | 828.00 K Decreased by -17.28% | -26.91 M Decreased by -153.56% | Decreased by -3.25 K% Decreased by -206.54% |
| Dec 31, 24 | 1.20 M Increased by +15.10% | -11.54 M Decreased by -6.57% | Decreased by -964.16% Increased by +7.41% |
| Sep 30, 24 | 1.17 M Increased by +49.68% | -12.37 M Increased by +12.93% | Decreased by -1.06 K% Increased by +41.83% |
| Jun 30, 24 | 976.00 K Increased by +513.84% | -11.01 M Increased by +3.30% | Decreased by -1.13 K% Increased by +84.25% |
| Mar 31, 24 | 1.00 M Increased by +124.44% | -10.61 M Increased by +34.68% | Decreased by -1.06 K% Increased by +70.90% |